Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
The persistent COVID-19 pandemic since 2020 has brought an enormous public health
burden to the global society and is accompanied by various evolution of the virus genome …
burden to the global society and is accompanied by various evolution of the virus genome …
[HTML][HTML] Therapeutics for COVID-19 and post COVID-19 complications: An update
Since its inception in late December 2020 in China, novel coronavirus has affected the
global socio-economic aspect. Currently, the world is seeking safe and effective treatment …
global socio-economic aspect. Currently, the world is seeking safe and effective treatment …
Identification of immunomodulatory drugs that inhibit multiple inflammasomes and impair SARS-CoV-2 infection
L de Almeida, ALN da Silva, TS Rodrigues… - Science …, 2022 - science.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces mild or
asymptomatic COVID-19 in most cases, but some patients develop an excessive …
asymptomatic COVID-19 in most cases, but some patients develop an excessive …
Tocilizumab administration for the treatment of hospitalized patients with COVID‐19: a systematic review and meta‐analysis
C Kyriakopoulos, G Ntritsos, A Gogali, H Milionis… - …, 2021 - Wiley Online Library
Tocilizumab has been repurposed against the 'cytokine storm'in the setting of coronavirus
disease 2019 (COVID‐19). Our aim was to evaluate the efficacy of tocilizumab in the …
disease 2019 (COVID‐19). Our aim was to evaluate the efficacy of tocilizumab in the …
The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19)
P Pagliano, C Sellitto, T Ascione… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction Molnupiravir (MOV) is a broad-spectrum oral antiviral agent approved for the
treatment of COVID-19. The results from in vitro and in vivo studies suggested MOV activity …
treatment of COVID-19. The results from in vitro and in vivo studies suggested MOV activity …
AI-Driven Discovery of SARS-CoV-2 Main Protease Fragment-like Inhibitors with Antiviral Activity In Vitro
LC Saramago, MV Santana, BF Gomes… - Journal of Chemical …, 2023 - ACS Publications
SARS-CoV-2 is the causative agent of COVID-19 and is responsible for the current global
pandemic. The viral genome contains 5 major open reading frames of which the largest …
pandemic. The viral genome contains 5 major open reading frames of which the largest …
Seven classes of antiviral agents
A Ianevski, S Ahmad, K Anunnitipat… - Cellular and Molecular …, 2022 - Springer
The viral epidemics and pandemics have stimulated the development of known and the
discovery of novel antiviral agents. About a hundred mono-and combination antiviral drugs …
discovery of novel antiviral agents. About a hundred mono-and combination antiviral drugs …
Vandetanib blocks the cytokine storm in SARS-CoV-2-infected mice
The portfolio of SARS-CoV-2 small molecule drugs is currently limited to a handful that are
either approved (remdesivir), emergency approved (dexamethasone, baricitinib, paxlovid …
either approved (remdesivir), emergency approved (dexamethasone, baricitinib, paxlovid …
[HTML][HTML] Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform
Reliable, easy-to-handle phenotypic screening platforms are needed for the identification of
anti-SARS-CoV-2 compounds. Here, we present caspase 3/7 activity as a readout for …
anti-SARS-CoV-2 compounds. Here, we present caspase 3/7 activity as a readout for …
Breaking bad: inflammasome activation by respiratory viruses
JA Cerato, EF da Silva, BN Porto - Biology, 2023 - mdpi.com
Simple Summary Inflammasomes are multiprotein complexes that sense endogenous
damage stimuli and diverse microbial pathogens, including viruses. A growing body of …
damage stimuli and diverse microbial pathogens, including viruses. A growing body of …